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transplants were 6/10 or higher match. 56 (52%) patients
were transplanted in CR1/PR1, 39 (36%) had stable disease or
<PR and 13 (12%) had resistant or refractory disease. The
CMV status was 26 (25%) D-/R-; 40 (39%) D-/R+, 5 (5%) D+/R-
and 32 (31%) D+/R+. 61 (56%) patients received ABO
compatible transplant, 26 (24%) had a minor incompatibility
and 22 (20%) had a major incompatibility.
The major ABO incompatibility group showed a trend
towards inferior survival compared to both ABO compatible
or minor ABO incompatible transplants. When evaluating
conditioning regimens separately similar trend was seen
among MA, NMA and RIC transplants, but did not reach
statistical signiﬁcance.
No difference was seen in the following factors: gender,
age at SCT, CMV status, acute or chronic GVHD.
Conclusion: In our experience, the use of a major ABO
incompatible donor may represent a risk factor for outcome
of ALLOSCT. Analysis of a larger cohort of patients may pro-
vide further understanding of the impact of ABO compati-
bility on ALLOSCT outcome.333
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Mismatched Related Haplo e Identical SCT
UPN 11/2488 13/0765
Age(y)/ sex 29 / M 30 / M
Diagnosis Relapsed AML CML - AP
Disease status Progressive diseases Progressive disease
Donor Sister Brother
Age (y)/sex 33 / F 33 / M
Stem cell CD34+/kg 5.88 x 106 5.6 x 106
MNC/kg 4.33 x 108 5.3 x 108
engraftment D+14 D +17
Mucositis Gr II Gr III/ IV
GVHD - Gr I
Stay length 47 days 38 days
D+28 chimerism 100% 100%
status Alive +395 Died +60 DAHTransplant, Tata Medical Center, Kolkata, India; 2 Clinical
Haematology & Bone Marrow Transplant, TMC, Kolkata, India;
3 Tata medical Center, Kolkata, India; 4 Clinical Haematology,
Tata Medical Center, Kolkata, India; 5 Clinical Hematology &
Bone Marrow Transplant, Apollo Hospital, Bangalore, India;
6 BMT Nursing, Tata medical Center, Kolkata, India
Five patients with progressive disease were transplanted
using the John’s Hopkins protocol but with IV busulphan
3.2mg/kg/day x 4 days given along with ﬂudarabine. The
donors were all siblings and the graft was peripheral blood
stem cells harvested after 4 days of G-CSF. Table I gives the
details of these patients.
All patients had progressive disease and the patient with
AML in ﬁrst relapse with 30% blasts at the time of transplant
(UPN 11/2488) is now one year post transplant with 100%
donor chimerism and no graft versus host disease.. The
protocol is well tolerated with rapid engraftment ( day +14-
17), a very low incidence of mucositits and no VOD. One
patient with CML and earlier blast transformation who had
received multiple rounds of chemotherapy and was in
accelerated phase at the time of transplant died of respira-
tory failure with a presumptive diagnosis of Diffuse Alveolar
Haemorrhage which could be related to busulphan. The pa-
tient with progressive NK T cell lymphoma who had failed
CHOP, and SMILE rejected his graft after achieving full donor
chimerism and succumbed to sepsis with multi-organ failure
while pancytopenic.
The addition of myelablationwith IV busulphan to the John’s
Hopkins protocol of PT-Cy is feasible and may reduce the
frequency of relapse.334
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26 / M 35 / M 25 / F
CML - AP NK Cell Lymphoma PCL
Progressive disease Progressive disease Progressive disease
Brother Brother Brother
27 / M 38 / M 32 / M
2.24 x 106 5.7 x 106 8.0 x 106
3.46 x 108 12.4 x 108 6.72 x 108
D +15 - D +14
Gr I Gr IV Gr III
-
27 days 36 days 28 days
93% 99.9% (11/09)
64.3% (17/09)
99.8%
Alive +60 Died Alive
